NASDAQ: SGP
Spyglass Pharma Inc Earnings Dates, Reports, Calls

Spyglass Pharma earnings were -$39.9M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest SGP earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$12.6M, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SGP reported annual earnings of -$39.9M, with 36.7% growth.

SGP earnings history

Current Revenue
$0.0
Current Earnings
-$39.9M
Current Profit Margin
0%

SGP Return on Equity

Insufficient data to display

SGP Return on Assets

Current Company
-57.3%
Current Industry
5.5%
SGP is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SGP announces earnings.

SGP Return on Capital Employed

Current Company
-37.16%
Current Industry
9.6%

SGP vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SGP-$38.87M-$39.87MN/A-$17.98
BVS$94.66M$22.73M-17.51%$0.34
IART-$326.40M-$516.47MN/A-$6.74
CBLL-$50.28M-$53.41MN/A-$1.46
INMD$111.03M$93.83M+6.87%$1.45

Spyglass Pharma Earnings Reports & History FAQ

What were Spyglass Pharma's earnings last quarter?

Spyglass Pharma (NASDAQ: SGP) reported Q4 2025 earnings per share (EPS) of -$5.70, up 24.18% year over year. Total SGP earnings for the quarter were -$12.56 million. In the same quarter last year, Spyglass Pharma's earnings per share (EPS) was -$4.59.

If you're new to stock investing, here's how to buy Spyglass Pharma stock.

Is Spyglass Pharma profitable or losing money?

As of the last Spyglass Pharma earnings report, Spyglass Pharma is currently losing money. Spyglass Pharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$39.87 million, a 36.71% increase year over year.

What was SGP's earnings growth in the past year?

As of Spyglass Pharma's earnings date in Q1 2026, Spyglass Pharma's earnings has grown year over year. SGP earnings in the past year totalled -$39.87 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.